Cognition Therapeutics (CGTX) said late Tuesday it has closed a direct offering of 14.7 million shares at $2.05 apiece to two new institutional investors, raising around $30 million.
The company said the proceeds will help support its phase 3 development of zervimesine for neurodegenerative disorders.